Daniel Richner

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

HBM Healthcare Investments AG is a listed investment company which invests worldwide, primarily focusing on Europe, Asia and North America, in private and public companies in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. It aims to invest mainly in a form of equity, but also considers convertible bonds, debt securities and derivatives. The investment focus is on later stage companies, and participates in follow-on investment rounds, also acquiring majority stake in target companies. It invests also in other funds.

M+R Spedag Group AG engages in the provision of logistics services. It offers international transport & logistics services such as European overland, ocean and airfreight, project & textile logistics, warehousing and contract logistics & distribution services. The firm has offices in France, China, Hong Kong, Indonesia, Korea, Singapore, Taiwan, Thailand, Burundi, D. R. Congo, Kenya, Morocco, Rwanda, South Africa, Sudan, Tanzania, Uganda, Mexico and The USA. M+R Spedag Group was founded in 1952 by Roger Metzger & Hansruedi Richner and is headquartered in Muttenz, Switzerland.

Pevion Biotech AG develops efficient and safe vaccines based on proprietary technology. The firm provides preclinical and clinical development of prophylactic/therapeutic vaccines based on its virosome-based technology platform. The company was founded in 2002 and is headquartered in Ittigen, Switzerland.